Search Results - "Majidpoor, Jamal"
-
1
Steps in metastasis: an updated review
Published in Medical oncology (Northwood, London, England) (01-01-2021)“…Metastasis is the most complex and deadly event. Tumor-stromal interface is a place where invasion of tumor cells in the form of single-cell or collective…”
Get full text
Journal Article -
2
Angiogenesis as a hallmark of solid tumors - clinical perspectives
Published in Cellular oncology (Dordrecht) (01-08-2021)“…Background Angiogenesis is a key and early step in tumorigenesis, and is known as a hallmark of solid tumors and a key promoter of tumor recurrence. Unlike…”
Get full text
Journal Article -
3
Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
Published in Biomedicine & pharmacotherapy (01-01-2022)“…Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)…”
Get full text
Journal Article -
4
Key promoters of tumor hallmarks
Published in International journal of clinical oncology (2022)“…Evolution of tumor hallmarks is a result of accommodation of tumor cells with their nearby milieu called tumor microenvironment (TME). Accommodation or…”
Get full text
Journal Article -
5
Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1
Published in Biomedicine & pharmacotherapy (01-07-2023)“…CD8+ T cells are the front-line defensive cells against cancer. Reduced infiltration and effector function of CD8+ T cells occurs in cancer and is contributed…”
Get full text
Journal Article -
6
The current knowledge concerning solid cancer and therapy
Published in Journal of biochemical and molecular toxicology (01-11-2021)“…Solid cancers comprise a large number of new cases and deaths from cancer each year globally. There are a number of strategies for addressing tumors raised…”
Get full text
Journal Article -
7
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
Published in Cellular oncology (Dordrecht) (01-06-2022)“…Macrophages are the most abundant and one of the most critical cells of tumor immunity. They provide a bridge between innate and adaptive immunity through…”
Get full text
Journal Article -
8
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Published in Biomedicine & pharmacotherapy (01-12-2022)“…Tumor microenvironment (TME) takes critical roles in tumor resistance to immune checkpoint inhibitors (ICIs) including anti-programmed death-1 (PD-1) or…”
Get full text
Journal Article -
9
(Im)maturity in Tumor Ecosystem
Published in Frontiers in oncology (25-01-2022)“…Tumors have special features that make them distinct from their normal counterparts. Immature cells in a tumor mass and their critical contributions to the…”
Get full text
Journal Article -
10
CD8 + T Cells in SARS-CoV-2 Induced Disease and Cancer-Clinical Perspectives
Published in Frontiers in immunology (01-04-2022)“…Dysregulated innate and adaptive immunity is a sign of SARS-CoV-2-induced disease and cancer. CD8 T cells are important cells of the immune system. The cells…”
Get full text
Journal Article -
11
Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors
Published in Biomedicine & pharmacotherapy (01-06-2023)“…Immune checkpoint inhibitor (ICI) resistance demands for acquisition of novel strategies in order to broaden the therapeutic repertoire of advanced cancers…”
Get full text
Journal Article -
12
Macrophage polarity in cancer: A review
Published in Journal of cellular biochemistry (01-03-2019)“…Macrophages are the most abundant cells within the tumor stroma displaying noticeable plasticity, which allows them to perform several functions within the…”
Get full text
Journal Article -
13
Checkpoint inhibitor/interleukin‐based combination therapy of cancer
Published in Cancer medicine (Malden, MA) (01-08-2022)“…Background Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the…”
Get full text
Journal Article -
14
Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Published in Biomedicine & pharmacotherapy (01-02-2023)“…Resistance to immune checkpoint inhibitors (ICIs) is a major issue of the current era in cancer immunotherapy. Immune evasion is a multi-factorial event, which…”
Get full text
Journal Article -
15
Cellular immune states in SARS-CoV-2-induced disease
Published in Frontiers in immunology (23-11-2022)“…The general immune state plays important roles against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Cells of the immune system are…”
Get full text
Journal Article -
16
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Published in Biomedicine & pharmacotherapy (01-06-2023)“…Extending the durability of response is the current focus in cancer immunotherapy with immune checkpoint inhibitors (ICIs). However, factors like…”
Get full text
Journal Article -
17
An update on the role of miR-124 in the pathogenesis of human disorders
Published in Biomedicine & pharmacotherapy (01-03-2021)“…[Display omitted] MicroRNA-124 (miR-124) is a copious miRNA in the brain, but it is expressed in a wide range of human/animal tissues participating in the…”
Get full text
Journal Article -
18
Regulatory role of microRNAs on PTEN signaling
Published in Biomedicine & pharmacotherapy (01-01-2021)“…Phosphatase and tensin homolog (PTEN) gene encodes a tumor suppressor protein which is altered in several malignancies. This protein is a negative regulator of…”
Get full text
Journal Article -
19
The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
Published in Biomedicine & pharmacotherapy (01-05-2023)“…Immunotherapy has revolutionized treatment of cancer during the last decades. Oncolytic virotherapy has also emerged as a strategy to fight against cancer…”
Get full text
Journal Article -
20
Alternative immune checkpoints in immunoregulatory profile of cancer stem cells
Published in Heliyon (01-12-2023)“…Tumor-mediated bypass of immune checkpoint inhibitor (ICI) therapy with anti-programmed death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1, also called…”
Get full text
Journal Article